Establish Diagnostic Models Based On Portal Venous Blood For Pancreatic Cancer

Study Overview

Establish Diagnostic Models Based on Portal Venous Blood for Pancreatic Cancer

Explore new markers based on portal venous blood sampling to establish novel diagnostic models for identification of malignant pancreatic mass.

EUS-FNA combined cytology detection is an important method for clinical diagnosis of squamous cell carcinoma. However, due to factors such as sampling method, smear making, staining technique, lower levels of the pathologists and other factors, its diagnostic sensitivity is still not very satisfactory. Poor diagnostic efficacy usually means another puncture, longer hospital stay, more medications and a higher incidence of adverse events. Missed diagnosis continuously directly delays the treatment time of the disease and seriously affects the patient's prognosis. Therefore, how to use new technologies to improve the differential diagnosis efficiency of benign and malignant pancreatic occupants is the key to improving the prognosis of diabetic cancer patients. The portal vein blood comes from the venous tract, including the blood flowing from the plasma to the liver. By collecting blood samples from the patient's portal vein, clinicians can separate more information from the patient. Studies have shown that the portal vein blood can be collected by ultrasound endoscopic puncture. This method is less traumatic, convenient and safe, and more information about the retinal tissue can be obtained. It is an important way to improve the efficiency of patient diagnosis. This study intends to use ultrasound endoscopic puncture technology to obtain portal vein blood, and use big data and ctDNA, metabolomics, exosomes and other different omics methods to screen the potential value of volume-occupying benign and malignant differential diagnosis markers in portal vein blood. Peripheral blood will simultaneously be collected to evaluate the efficacy of these newly developed markers.

Diagnoses Disease

DIAGNOSTIC_TEST: Endoscopic Ultrasound (EUS), Fine Needle Aspiration

EMPVC

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2020-08-18	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2024-03-28
First Submitted that Met QC Criteria 2020-08-28	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2024-03-29
First Posted (ACTUAL) 2020-09-02	Results First Posted N/A	Last Verified 2024-03

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A

Allocation:
N/A

Interventional Model:
N/A

Masking:
N/A

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
: pancreatic mass diagnosed benign Through pathological examination, radiological examination and follow-up, these patients are finally diagnosed with benign pancreatic mass.	DIAGNOSTIC_TEST: Endoscopic Ultrasound (EUS), Fine Needle Aspiration Endoscopic Ultrasound (EUS), Fine Needle Aspiration, which are routine clinical operations
: pancreatic mass diagnosed malignant Through pathological examination, radiological examination and follow-up, these patients are finally diagnosed with pancreaitic cancer.	DIAGNOSTIC_TEST: Endoscopic Ultrasound (EUS), Fine Needle Aspiration Endoscopic Ultrasound (EUS), Fine Needle Aspiration, which are routine clinical operations

Participant Group/Arm

Intervention/Treatment

: pancreatic mass diagnosed benign

Through pathological examination, radiological examination and follow-up, these patients are finally diagnosed with benign pancreatic mass.

DIAGNOSTIC_TEST: Endoscopic Ultrasound (EUS), Fine Needle Aspiration

Endoscopic Ultrasound (EUS), Fine Needle Aspiration, which are routine clinical operations

: pancreatic mass diagnosed malignant

Through pathological examination, radiological examination and follow-up, these patients are finally diagnosed with pancreaitic cancer.

DIAGNOSTIC_TEST: Endoscopic Ultrasound (EUS), Fine Needle Aspiration

Endoscopic Ultrasound (EUS), Fine Needle Aspiration, which are routine clinical operations

Primary Outcome Measures	Measure Description	Time Frame
Status of survival	To varify if the patients died becaused of malignant pancreatic cancer.	through study completion, an average of 1 year

Secondary Outcome Measures	Measure Description	Time Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Xiangyu Kong, MD

Phone Number: 13564644397

Email: xiangyukong185@hotmail.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

PRINCIPAL_INVESTIGATOR: Kaixuan Wang, MD, Changhai Hospital

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

Patients

Caregivers

Clinical Trial Record